BACKGROUND AND PURPOSE: Eupalmerin acetate (EPA) is a marine diterpene compound isolated from the gorgonian octocorals Eunicea succinea and Eunicea mammosa. The compound has been previously shown to modulate muscle-type and neuronal nicotinic acetylcholine receptors, which are inhibited in the presence of low micromolar concentrations of EPA. In this study, we examined the effect of EPA on another transmitter-gated ion channel, the GABA(A) receptor. EXPERIMENTAL APPROACH: Whole-cell and single-channel recordings were made from HEK 293 cells transiently expressing rat wild-type and mutant alpha1beta2gamma2L GABA(A) receptors. KEY RESULTS: Our findings demonstrate that, at micromolar concentrations, EPA potentiates the rat alpha1beta2gamma2L GABA(A) receptor. The analysis of single-channel currents recorded in the presence of EPA showed that the kinetic mode of action of EPA is similar to that of neuroactive steroids. Mutations to residues alpha1Q241 and alpha1N407/Y410, previously shown to affect receptor modulation by neurosteroids, also diminished potentiation by EPA. Exposure to a steroid antagonist, (3alpha,5alpha)-17-phenylandrost-16-en-3-ol, reduced potentiation by EPA. Additionally, exposure to EPA led to potentiation of GABA(A) receptors activated by very high concentrations (1-10 microM) of allopregnanolone. In tadpole behavioural assays, EPA caused loss of righting reflex and loss of swimming reflex. CONCLUSIONS AND IMPLICATIONS: We conclude that EPA either interacts with the putative neurosteroid binding site on the GABA(A) receptor or shares with neurosteroids the key transduction elements involved in channel potentiation by steroids. The results indicate that cembranoids represent a novel class of GABA(A) receptor modulators.
BACKGROUND AND PURPOSE:Eupalmerin acetate (EPA) is a marine diterpene compound isolated from the gorgonian octocorals Eunicea succinea and Eunicea mammosa. The compound has been previously shown to modulate muscle-type and neuronal nicotinic acetylcholine receptors, which are inhibited in the presence of low micromolar concentrations of EPA. In this study, we examined the effect of EPA on another transmitter-gated ion channel, the GABA(A) receptor. EXPERIMENTAL APPROACH: Whole-cell and single-channel recordings were made from HEK 293 cells transiently expressing rat wild-type and mutant alpha1beta2gamma2L GABA(A) receptors. KEY RESULTS: Our findings demonstrate that, at micromolar concentrations, EPA potentiates the rat alpha1beta2gamma2L GABA(A) receptor. The analysis of single-channel currents recorded in the presence of EPA showed that the kinetic mode of action of EPA is similar to that of neuroactive steroids. Mutations to residues alpha1Q241 and alpha1N407/Y410, previously shown to affect receptor modulation by neurosteroids, also diminished potentiation by EPA. Exposure to a steroid antagonist, (3alpha,5alpha)-17-phenylandrost-16-en-3-ol, reduced potentiation by EPA. Additionally, exposure to EPA led to potentiation of GABA(A) receptors activated by very high concentrations (1-10 microM) of allopregnanolone. In tadpole behavioural assays, EPA caused loss of righting reflex and loss of swimming reflex. CONCLUSIONS AND IMPLICATIONS: We conclude that EPA either interacts with the putative neurosteroid binding site on the GABA(A) receptor or shares with neurosteroids the key transduction elements involved in channel potentiation by steroids. The results indicate that cembranoids represent a novel class of GABA(A) receptor modulators.
Authors: P A Ferchmin; R J Lukas; R M Hann; J D Fryer; J B Eaton; O R Pagán; A D Rodríguez; Y Nicolau; M Rosado; S Cortés; V A Eterović Journal: J Neurosci Res Date: 2001-04-01 Impact factor: 4.164
Authors: Swapnali S Sawant; Diaa T A Youssef; Jane Reiland; Melissa Ferniz; Dario Marchetti; Khalid A El Sayed Journal: J Nat Prod Date: 2006-07 Impact factor: 4.050
Authors: A Jenkins; E P Greenblatt; H J Faulkner; E Bertaccini; A Light; A Lin; A Andreasen; A Viner; J R Trudell; N L Harrison Journal: J Neurosci Date: 2001-03-15 Impact factor: 6.167
Authors: Fernando Reyes; Ana Ardá; Rocío Martín; Rogelio Fernández; Ana Rueda; David Montalvo; Cristina Gómez; Carlos Jiménez; Jaime Rodríguez; José Maria Sánchez-Puelles Journal: J Nat Prod Date: 2004-07 Impact factor: 4.050
Authors: Delia Belelli; Anna-Lisa Muntoni; Simon D Merrywest; Luc J Gentet; Anna Casula; Helen Callachan; Paola Madau; David K Gemmell; Niall M Hamilton; Jeremy J Lambert; Keith T Sillar; John A Peters Journal: Neuropharmacology Date: 2003-07 Impact factor: 5.250
Authors: Ping Li; John Bracamontes; Bryson W Katona; Douglas F Covey; Joe Henry Steinbach; Gustav Akk Journal: Mol Pharmacol Date: 2007-03-06 Impact factor: 4.436
Authors: Mariangela Chisari; Lawrence N Eisenman; Douglas F Covey; Steven Mennerick; Charles F Zorumski Journal: Trends Neurosci Date: 2010-04-19 Impact factor: 13.837
Authors: P A Ferchmin; Oné R Pagán; Henning Ulrich; Ada C Szeto; Richard M Hann; Vesna A Eterović Journal: Toxicon Date: 2009-03-10 Impact factor: 3.033
Authors: Oné R Pagán; Amanda L Rowlands; Angela L Fattore; Tamara Coudron; Kimberly R Urban; Apurva H Bidja; Vesna A Eterović Journal: Eur J Pharmacol Date: 2009-05-30 Impact factor: 4.432
Authors: Ping Li; Achintya K Bandyopadhyaya; Douglas F Covey; Joe Henry Steinbach; Gustav Akk Journal: Br J Pharmacol Date: 2009-08-20 Impact factor: 8.739
Authors: Gustav Akk; Ping Li; John Bracamontes; David E Reichert; Douglas F Covey; Joe Henry Steinbach Journal: Mol Pharmacol Date: 2008-06-10 Impact factor: 4.436